Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BenevolentAI Goes Public In Europe’s Largest SPAC

Valued at €1.5bn

Executive Summary

The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.

You may also be interested in...



Seismic Hopes To Shake Up Immunology With New Financing

Financing Snapshot: The AI/ML-focused company raised $101m in a series A round and plans to use the funding to develop immunoglobulin- and cell-mediated autoimmune disorder drugs.

AstraZeneca And BenevolentAI Advance AI Partnership With Second Novel Target

AstraZeneca and BenevolentAI claim their partnership is augmenting and accelerating validation of new drug targets.

Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go

Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel